Header Logo

Connection

GAURI R VARADHACHARY to Disease-Free Survival

Back to Details
This is a "connection" page, showing publications GAURI R VARADHACHARY has written about Disease-Free Survival.
GAURI R VARADHACHARY
Connection Strength
0.325
Disease-Free Survival
  1. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008 Jul 20; 26(21):3487-95.
    View in: PubMed
    Score: 0.035
  2. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Pancreatology. 2021 Jan; 21(1):200-207.
    View in: PubMed
    Score: 0.020
  3. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology. 2020 Apr; 20(3):501-504.
    View in: PubMed
    Score: 0.019
  4. Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. Pancreas. 2017 10; 46(9):1180-1187.
    View in: PubMed
    Score: 0.016
  5. Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy. Am J Surg Pathol. 2017 Aug; 41(8):1097-1104.
    View in: PubMed
    Score: 0.016
  6. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Ann Oncol. 2017 04 01; 28(4):741-747.
    View in: PubMed
    Score: 0.016
  7. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):755-65.
    View in: PubMed
    Score: 0.015
  8. Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. Am J Surg Pathol. 2015 Oct; 39(10):1395-403.
    View in: PubMed
    Score: 0.014
  9. The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy. Histopathology. 2016 Jan; 68(2):210-20.
    View in: PubMed
    Score: 0.014
  10. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Acta Oncol. 2015 Jul; 54(7):971-8.
    View in: PubMed
    Score: 0.014
  11. Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg. 2014 Feb; 18(2):269-78; discussion 278.
    View in: PubMed
    Score: 0.013
  12. Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol. 2013 Jul; 20(7):2197-203.
    View in: PubMed
    Score: 0.012
  13. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2012 Mar; 36(3):409-17.
    View in: PubMed
    Score: 0.011
  14. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford). 2012 Jun; 14(6):365-72.
    View in: PubMed
    Score: 0.011
  15. Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2012 Aug 01; 118(15):3801-11.
    View in: PubMed
    Score: 0.011
  16. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J Gastrointest Surg. 2012 Jan; 16(1):68-78; discussion 78-9.
    View in: PubMed
    Score: 0.011
  17. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol. 2012 Jan; 16(1):29-37.
    View in: PubMed
    Score: 0.011
  18. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2012 Jan 01; 118(1):268-77.
    View in: PubMed
    Score: 0.011
  19. Role of definitive radiation therapy in carcinoma of unknown primary in the abdomen and pelvis. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):2012-7.
    View in: PubMed
    Score: 0.011
  20. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs. 2011 Aug; 29(4):694-9.
    View in: PubMed
    Score: 0.010
  21. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 2008 Oct 15; 113(8):2046-52.
    View in: PubMed
    Score: 0.009
  22. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct; 26(8):794-9.
    View in: PubMed
    Score: 0.009
  23. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008 Jul 20; 26(21):3496-502.
    View in: PubMed
    Score: 0.009
  24. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer. 2006 Dec 01; 107(11):2589-96.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.